https://www.selleckchem.com/pr....oducts/Fedratinib-SA
3%) patients were treated in compliance with the ABC pathway. During 1-year follow-up, 207 composite outcome events and 87 deaths occurred. Mortality was significantly lower in the ABC group vs non-ABC (5.8% vs 15.9%, P=.0014, respectively). On multivariate analysis, ABC compliance was associated with a lower risk of all-cause death and the composite outcome after 6months (OR 0.18; 95% CI 0.42-0.75 and OR 0.54; 95% Cl 0.30-1.00, respectively) and at 1year (OR 0.30; 95% Cl 0.11-0.76 and OR 0.57; 95% Cl 0.33-0.97, re
Aimer
Commentaire
Partagez
